Gilead Sciences Inc. (GILD) and Bristol-Myers Squibb Co. (BMY) cured all
patients in a trial, demonstrating the success of a cocktail
that may never be approved.
In a study among 41 patients of Gilead’s sofosbuvir with
Bristol’s daclatasvir, with or without the generic antiviral
ribavirin, 40 were virus-free 12 weeks after six months of
treatment, according to results presented yesterday in
Amsterdam. The other patient didn’t turn up to the last
appointment and was later found to be virus-clear. All the
patients had failed prior treatment with either Vertex
Pharmaceuticals Inc. (VRTX)’s Incivek or Merck & Co. (MRK)’s Victrelis.